clinical trial · NCT06649344
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Fujian Shengdi Pharmaceutical Co., Ltd.·phase3·completed·n = 884
Type 2 DiabetesHRS9531 InjectionSemaglutide Injection
brief summary
The study is being conducted to evaluate the efficacy and safety of HRS9531 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Semaglutide QW for 36 weeks and 52 weeks.
started
Oct 31, 2024
primary completion
Jul 18, 2026
completion
Jul 18, 2026
last updated
Jul 30, 2026
official title
A Phase III,Multicenter,Randomized,Open-label,Parallel-controlled Study Comparing the Efficacy and Safety of HRS9531 With Semaglutide in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin Monotherapy or in Combination With SGLT2 Inhibitors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol